We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Health, Inc. (HIMS) Falls More Steeply Than Broader Market: What Investors Need to Know
Read MoreHide Full Article
In the latest trading session, Hims & Hers Health, Inc. (HIMS - Free Report) closed at $27.93, marking a -3.07% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.45%. Elsewhere, the Dow saw a downswing of 0.63%, while the tech-heavy Nasdaq depreciated by 0.78%.
Prior to today's trading, shares of the company had gained 0.7% outpaced the Medical sector's gain of 0.57% and the S&P 500's loss of 1.99%.
The investment community will be paying close attention to the earnings performance of Hims & Hers Health, Inc. in its upcoming release. It is anticipated that the company will report an EPS of $0.08, marking a 33.33% rise compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $894.51 million, up 49.34% from the prior-year quarter.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.83 per share and revenue of $3.22 billion. These totals would mark changes of -256.6% and +37.2%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Hims & Hers Health, Inc. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Currently, Hims & Hers Health, Inc. is carrying a Zacks Rank of #3 (Hold).
The Medical Info Systems industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 85, positioning it in the top 35% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow HIMS in the coming trading sessions, be sure to utilize Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Hims & Hers Health, Inc. (HIMS) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest trading session, Hims & Hers Health, Inc. (HIMS - Free Report) closed at $27.93, marking a -3.07% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.45%. Elsewhere, the Dow saw a downswing of 0.63%, while the tech-heavy Nasdaq depreciated by 0.78%.
Prior to today's trading, shares of the company had gained 0.7% outpaced the Medical sector's gain of 0.57% and the S&P 500's loss of 1.99%.
The investment community will be paying close attention to the earnings performance of Hims & Hers Health, Inc. in its upcoming release. It is anticipated that the company will report an EPS of $0.08, marking a 33.33% rise compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $894.51 million, up 49.34% from the prior-year quarter.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.83 per share and revenue of $3.22 billion. These totals would mark changes of -256.6% and +37.2%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Hims & Hers Health, Inc. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Currently, Hims & Hers Health, Inc. is carrying a Zacks Rank of #3 (Hold).
The Medical Info Systems industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 85, positioning it in the top 35% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow HIMS in the coming trading sessions, be sure to utilize Zacks.com.